Named on 7 rounds in the feed, most often in Biotech.
Rounds from 2019-04-08 to 2026-11-05
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
T-Therapeutics A biotechnology company developing next-generation T cell receptor (TCR) T cell engager (TCE) therapeutics for cancer and autoimmune diseases | Series B Verified against 1 of 77 sources | $133M | 2026-11-05 | [ PART ] |
SonoThera SonoThera develops innovative ultrasound-mediated nonviral genetic therapies targeting various medical conditions. | Series B Verified against 1 of 7 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $125M | 2026-06-10 | [ PART ] |
Link Cell Therapies An oncology cell therapy company utilizing its proprietary logic-gating technology to develop next-generation CAR-T therapeutics for solid tumors and hematologic malignancies | Series A Verified against 1 of 4 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $60M | 2025-12-15 | [ LEAD ] |
HistoSonics HistoSonics® is developing a non-invasive, robotically assisted platform capable of destroying tissue at a sub-cellular level. | Series D Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $102M | 2024-08-15 | [ PART ] |
SonoThera SonoThera develops innovative ultrasound-mediated nonviral genetic therapies targeting various medical conditions. | Series A Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $60.8M | 2022-12-05 | [ PART ] |
HistoSonics HistoSonics® is developing a non-invasive, robotically assisted platform capable of destroying tissue at a sub-cellular level. | Series C Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $40M | 2020-06-08 | [ PART ] |
HistoSonics HistoSonics® is developing a non-invasive, robotically assisted platform capable of destroying tissue at a sub-cellular level. | Series C Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $54M | 2019-04-08 | [ PART ] |